Navigation Links
Garland Andres, NP-C, Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
Date:3/23/2013

Atlanta, GA (PRWEB) March 23, 2013

InTone, developed by InControl Medical, LLC, is a medical device available by prescription, indicated for the treatment of stress incontinence, urge incontinence or mixed (stress and urge) incontinence. Available by prescription, InTone combines a daily program of volitional exercises, voice-guided instruction, biofeedback and micro-current stimulation to strengthen muscle tone in the pelvic floor.

Stress incontinence can occur when lifting, sneezing, coughing, laughing or exercising. Urge incontinence is the unwanted and sudden need to urinate. Both can be caused or exacerbated by childbirth, obesity, excessive exercise, lack of exercise, age or trauma.

According to the National Association for Continence, up to 30 million women in America have experienced bladder leakage issues. About one in four new mothers experience “leaking” following normal delivery, and about one in six following cesarean section.

Up to two-thirds of women who “leak” have never mentioned it to their physicians, and up to two-thirds of women do not use any treatment or product to manage their bladder leakage.

Until now, available options had mixed results. Absorbent pads and diapers do nothing to treat the condition. Medications, if prescribed, can cause side effects and are not always effective. Surgery, if performed, is a more invasive option, and is not always effective. Research has shown that even when properly taught how to perform pelvic floor, or Kegel, exercises, about half of all women do them incorrectly.

When asked about treating incontinence Garland Andres, NP-C, stated “I'm excited to offer a nonsurgical option for the treatment of incontinence. I think it will be of great benefit for my patients."

After prescribing InTone, the physician customizes the settings for InTone and the patient is shown how to use it at home. A sensor in the unit measures pressure to determine if the patient is doing the exercises properly. The biofeedback unit uses voice-guided instruction to take her through the routine and reports her muscle isolation and strength. Each daily session takes about ten minutes, and data from each session is recorded. After two weeks or so, the physician analyzes the recorded data and adjusts InTone based on the patient’s progress, and at-home treatment sessions continue. Most patients should experience progress in a few weeks, and most patients should experience effective relief in 90 days.

InTone is available by prescription to patients in the United States. InTone was developed by InControl Medical, LLC, based in Brookfield, Wisconsin. InControl Medical provides specialty medical products for women’s health, and is sourced and manufactured entirely in the United States. More information on InTone can be found at http://www.incontrolmedical.com.

To contact Garland Andres, NP-C, please call (404) 255-3633 or go to the Northside Northpoint OB-GYN website, http://www.nsnpobgyn.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10561034.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Garland Canada Introduces White-Stallion® All-Purpose Primer for Metal Roofs
2. Loyola Cancer Center receives Outstanding Achievement Award
3. MU receives national award for using mind-body approach to improve health
4. Neuropsychologist receives University of Houstons highest faculty honor
5. Boston researcher, surgical oncologist receives national award
6. LA BioMed receives Grand Challenges Explorations grant
7. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
8. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
9. UC San Diego Superfund Research Program receives $15 million grant renewal
10. Markey receives $6.25 million to study deadly blood and bone marrow disease
11. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Wegener Polyangiitis - Pipeline ... Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 2015, ... pipeline. This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
(Date:2/4/2016)... -- In response to the opioid abuse epidemic, today Dr. ... Products and Tobacco, along with other FDA leaders, called for ... opioid medications. The plan will focus on policies aimed at ... to effective relief. --> ... risk-benefit paradigm for opioids and ensure that the agency considers ...
Breaking Medicine Technology: